Renal cancer management is challenging from diagnosis to treatment and follow-up. In cases of small renal masses and cystic lesions the differential diagnosis of benign or malignant tissues has potential pitfalls when imaging or even renal biopsy is applied. The recent artificial intelligence, imaging techniques, and genomics advancements have the ability to help clinicians set the stratification risk, treatment selection, follow-up strategy, and prognosis of the disease. The combination of radiomics features and genomics data has achieved good results but is currently limited by the retrospective design and the small number of patients included in clinical trials. The road ahead for radiogenomics is open to new, well-designed prospective studies, with large cohorts of patients required to validate previously obtained results and enter clinical practice.

Radiogenomics in renal cancer management—current evidence and future prospects / Ferro, Matteo; Musi, Gennaro; Marchioni, Michele; Maggi, Martina; Veccia, Alessandro; DEL GIUDICE, Francesco; Barone, Biagio; Crocetto, Felice; Lasorsa, Francesco; Antonelli, Alessandro; Schips, Luigi; Autorino, Riccardo; Busetto, GIAN MARIA; Terracciano, Daniela; Lucarelli, GIUSEPPE TIZIANO; Sabin Tataru, Octavian. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:5(2023). [10.3390/ijms24054615]

Radiogenomics in renal cancer management—current evidence and future prospects

Martina Maggi;Francesco Del Giudice;Alessandro Antonelli;Luigi Schips;Gian Maria Busetto;Giuseppe Lucarelli
Penultimo
;
2023

Abstract

Renal cancer management is challenging from diagnosis to treatment and follow-up. In cases of small renal masses and cystic lesions the differential diagnosis of benign or malignant tissues has potential pitfalls when imaging or even renal biopsy is applied. The recent artificial intelligence, imaging techniques, and genomics advancements have the ability to help clinicians set the stratification risk, treatment selection, follow-up strategy, and prognosis of the disease. The combination of radiomics features and genomics data has achieved good results but is currently limited by the retrospective design and the small number of patients included in clinical trials. The road ahead for radiogenomics is open to new, well-designed prospective studies, with large cohorts of patients required to validate previously obtained results and enter clinical practice.
2023
renal cancer; radiomics; radiogenomics; genomics; artificial intelligence; machine learning
01 Pubblicazione su rivista::01a Articolo in rivista
Radiogenomics in renal cancer management—current evidence and future prospects / Ferro, Matteo; Musi, Gennaro; Marchioni, Michele; Maggi, Martina; Veccia, Alessandro; DEL GIUDICE, Francesco; Barone, Biagio; Crocetto, Felice; Lasorsa, Francesco; Antonelli, Alessandro; Schips, Luigi; Autorino, Riccardo; Busetto, GIAN MARIA; Terracciano, Daniela; Lucarelli, GIUSEPPE TIZIANO; Sabin Tataru, Octavian. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:5(2023). [10.3390/ijms24054615]
File allegati a questo prodotto
File Dimensione Formato  
Ferro_Radiogenomics in_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 740.13 kB
Formato Adobe PDF
740.13 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1672955
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 39
social impact